Literature DB >> 18587237

Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi.

C Borelli1, M Schaller, M Niewerth, K Nocker, B Baasner, D Berg, R Tiemann, K Tietjen, B Fugmann, S Lang-Fugmann, H C Korting.   

Abstract

BACKGROUND: In contrast to the increasing numbers of agents for the treatment of invasive fungal infections, discoveries of new antifungal agents with therapeutic value in dermatomycoses are reported only rarely.
METHODS: Abafungin (chemical abstracts service registry No. 129639-79/8) is the first member of a novel class of synthetic antifungal compounds, the arylguanidines. It was first synthesized at Bayer AG, Leverkusen, Germany, and its antifungal action was discovered during the screening of H(2)-receptor antagonists based on the structure of famotidine. To obtain insight into its mode of action and antifungal activity, various tests were carried out with different fungal pathogens in vitro.
RESULTS: Abafungin was found to have potent antifungal activity. Furthermore, mode-of-action studies suggested that abafungin exerts its antifungal activity regardless of whether the pathogens are growing or in a resting state. One target of abafungin was found to be the inhibition of transmethylation at the C-24 position of the sterol side chain, catalyzed by the enzyme sterol-C-24-methyltransferase. A second action of abafungin seems to be a direct effect on the fungal cell membrane.
CONCLUSION: The observed characteristics of abafungin indicate that abafungin might be a promising antifungal agent defining a new class of antimycotics. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587237      PMCID: PMC2818358          DOI: 10.1159/000142334

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  38 in total

1.  The echinocandin "target" identified by cross-linking is a homolog of Pil1 and Lsp1, sphingolipid-dependent regulators of cell wall integrity signaling.

Authors:  Thomas D Edlind; Santosh K Katiyar
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 2.  Currently used antimycotics: spectrum, mode of action and resistance occurrence.

Authors:  Isabelle E J A Francois; An M Aerts; Bruno P A Cammue; Karin Thevissen
Journal:  Curr Drug Targets       Date:  2005-12       Impact factor: 3.465

Review 3.  Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium.

Authors:  A Böhme; M Karthaus
Journal:  Chemotherapy       Date:  1999 Sep-Oct       Impact factor: 2.544

Review 4.  Emerging role of lipids of Candida albicans, a pathogenic dimorphic yeast.

Authors:  P Mishra; J Bolard; R Prasad
Journal:  Biochim Biophys Acta       Date:  1992-07-09

Review 5.  Antifungal drug resistance in pathogenic fungi.

Authors:  H Vanden Bossche; F Dromer; I Improvisi; M Lozano-Chiu; J H Rex; D Sanglard
Journal:  Med Mycol       Date:  1998       Impact factor: 4.076

Review 6.  Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

Authors:  M Haria; H M Bryson
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

7.  Two mechanisms of butenafine action in Candida albicans.

Authors:  W Iwatani; T Arika; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 8.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 9.  Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin.

Authors:  H C Korting; M Schäfer-Korting
Journal:  Arch Dermatol       Date:  1992-02

Review 10.  Recent advances and challenges in the treatment of invasive fungal infections.

Authors:  Pei-Lan Shao; Li-Min Huang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2007-10-24       Impact factor: 5.283

View more
  13 in total

1.  Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans.

Authors:  Ahmed Khalil; Jessica A Edwards; Chad A Rappleye; Werner Tjarks
Journal:  Bioorg Med Chem       Date:  2014-12-10       Impact factor: 3.641

2.  Tulbaghia violacea (Harv) Exerts its Antifungal Activity by Reducing Ergosterol Production in Aspergillus flavus.

Authors:  Benesh M Somai; Vuyokazi Belewa; Carminita Frost
Journal:  Curr Microbiol       Date:  2021-06-08       Impact factor: 2.188

Review 3.  Thiazole: A Versatile Standalone Moiety Contributing to the Development of Various Drugs and Biologically Active Agents.

Authors:  Mohammed F Arshad; Aftab Alam; Abdullah Ayed Alshammari; Mohammed Bader Alhazza; Ibrahim Mohammed Alzimam; Md Anish Alam; Gulam Mustafa; Md Salahuddin Ansari; Abdulelah M Alotaibi; Abdullah A Alotaibi; Suresh Kumar; Syed Mohammed Basheeruddin Asdaq; Mohd Imran; Pran Kishore Deb; Katharigatta N Venugopala; Shahamah Jomah
Journal:  Molecules       Date:  2022-06-21       Impact factor: 4.927

Review 4.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

5.  Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.

Authors:  Jessica A Edwards; Megan M Kemski; Chad A Rappleye
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

6.  Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans.

Authors:  Keisuke Ishita; Stavros Stefanopoulos; Ahmed Khalil; Xiaolin Cheng; Werner Tjarks; Chad A Rappleye
Journal:  Bioorg Med Chem       Date:  2018-02-02       Impact factor: 3.641

7.  Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts.

Authors:  Kristie D Goughenour; Joan-Miquel Balada-Llasat; Chad A Rappleye
Journal:  J Clin Microbiol       Date:  2015-08-05       Impact factor: 5.948

Review 8.  N-Propargylamines: versatile building blocks in the construction of thiazole cores.

Authors:  S Arshadi; E Vessally; L Edjlali; R Hosseinzadeh-Khanmiri; E Ghorbani-Kalhor
Journal:  Beilstein J Org Chem       Date:  2017-03-30       Impact factor: 2.883

9.  Two inhibitors of yeast plasma membrane ATPase 1 (ScPma1p): toward the development of novel antifungal therapies.

Authors:  Sabine Ottilie; Gregory M Goldgof; Andrea L Cheung; Jennifer L Walker; Edgar Vigil; Kenneth E Allen; Yevgeniya Antonova-Koch; Carolyn W Slayman; Yo Suzuki; Jacob D Durrant
Journal:  J Cheminform       Date:  2018-02-20       Impact factor: 5.514

Review 10.  Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview.

Authors:  Dimitris Matiadis; Marina Sagnou
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.